Welcome to our dedicated page for Nutriband news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. (NASDAQ: NTRB, NASDAQ: NTRBW) generates news primarily around the development of its prescription transdermal pharmaceutical products and its proprietary AVERSA abuse-deterrent transdermal technology. The company’s updates frequently focus on its lead product under development, an abuse-deterrent fentanyl transdermal system known as AVERSA FENTANYL, and on efforts to address the risks of abuse, diversion, misuse, and accidental exposure associated with transdermal opioid therapies.
News about Nutriband often covers clinical and regulatory milestones, such as meetings with the U.S. Food and Drug Administration (FDA) to discuss Chemistry, Manufacturing, and Controls plans, regulatory pathways under the 505(b)(2) NDA framework, and feedback on studies designed to characterize abuse-deterrent properties. Press releases also highlight patent developments, including Notices of Allowance, newly issued patents for abuse and misuse deterrent transdermal systems, and provisional patent applications intended to enhance AVERSA’s aversive formulations and coating methods.
Investors following NTRB and NTRBW can also expect corporate and strategic news, including stock dividends of Series A Convertible Preferred Stock, exercises of stock options and warrants, and transactions such as the agreement to sell a majority interest in the Pocono Pharmaceutical subsidiary to EarthVision Bio. Nutriband’s communications may additionally cover index inclusions, shareholder letters discussing milestones and outlook, and participation in investor conferences where management presents operational highlights and the strategic direction of the AVERSA platform.
This news page aggregates these developments into a single feed, allowing readers to review Nutriband’s announcements on product development, intellectual property, regulatory interactions, capital structure, and strategic initiatives related to its abuse-deterrent transdermal technology and lead fentanyl patch program.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced a favorable court verdict regarding its 2017 acquisition of Advanced Health Brands, allowing the recovery of 4.8 million shares that had been issued as part of the deal. After a reverse split in 2018, this recovery translates to approximately 1.2 million shares, or 15% of the company’s total outstanding shares. This successful legal outcome is expected to reduce Nutriband's total outstanding shares, positively impacting shareholder value.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) endorses the updated CDC guidelines for opioid prescription, advocating for comprehensive pain management that includes responsible opioid use. The draft guidelines have received positive feedback, suggesting a need to ease restrictions for patients suffering from severe pain. Nutriband's AVERSA™ technology aims to prevent opioid abuse through its unique transdermal patches. This could lead to significant sales, estimated at $80M - $200M within five years. The company holds broad patent protections for this technology globally.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that CEO Gareth Sheridan will be featured on The RedChip Money Report on Bloomberg TV, airing on May 28 at 7 p.m. ET. This program, focused on small-cap investing, reaches approximately 73 million homes in the U.S. Nutriband is developing transdermal pharmaceutical products, including an abuse deterrent fentanyl patch utilizing AVERSA™ technology. The company aims to prevent misuse and accidental exposure to drugs with abuse potential. For more information, visit www.nutriband.com.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has been invited to present at the Emerging Growth Conference on May 25, 2022, at 2:00 p.m. Eastern time. This live online event allows shareholders and investors to engage with CEO Gareth Sheridan in real time. The presentation will last 30 minutes and include a Q&A session. An archived webcast will be available for those who cannot attend live. Nutriband focuses on developing transdermal pharmaceutical products, including an abuse deterrent fentanyl patch using AVERSA™ technology.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) reported $234,000 in new contract manufacturing orders through its subsidiary, Pocono Pharma, marking significant revenue growth. This amount surpasses the total revenue for Q2 2021. CEO Gareth Sheridan emphasized the importance of expanding revenue opportunities while advancing the development of their AVERSA abuse deterrent fentanyl patch. The company is focused on enhancing its portfolio of transdermal pharmaceutical products, indicated by the recent order volume.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced its subsidiary, Active Intelligence LLC, has registered as a Class I medical device manufacturer with the FDA. This registration enables the production and distribution of its proprietary AI Tape, aimed at the kinesiology tape market, valued over $5 billion and growing at a 6.8% CAGR. CEO Gareth Sheridan emphasized this milestone will drive commercial sales and open avenues for contract manufacturing. Active Intelligence is also developing medicated kinesiology tapes for sports injury recovery.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced that the USPTO published a patent for its AVERSA™ technology aimed at preventing opioid misuse through a transdermal system. The patent, US Patent 11,246,840, was issued on February 15, 2022, and supports the development of the AVERSA Fentanyl patch. Nutriband has entered a feasibility agreement with Kindeva Drug Delivery to incorporate this technology in its lead product candidate.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) will participate in Benzinga ALL ACCESS on February 4, 2022, featuring CEO Gareth Sheridan at 10AM ET. The event can be streamed live here. Nutriband specializes in developing transdermal pharmaceutical products, notably an abuse deterrent fentanyl patch utilizing their AVERSA™ technology. This technology aims to prevent the misuse and accidental exposure of drugs. For more details, visit www.nutriband.com.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced the receipt of a notification from the USPTO confirming the issuance of a patent for its AVERSA™ transdermal abuse deterrent technology.
This technology aims to prevent the misuse of drugs by incorporating aversive agents into transdermal patches. The patent secures the company’s lead product, AVERSA™ Fentanyl, which could become the first fentanyl patch with abuse deterrent properties. Nutriband is also expanding its pipeline to include other drugs, enhancing safety against misuse.
Nutriband Inc. (NASDAQ:NTRB, NTRBW) has expanded its product development pipeline for its AVERSA™ abuse deterrent transdermal technology. The lead product, AVERSA Fentanyl, could tap into a market worth $80 - $200 million. Additionally, AVERSA buprenorphine and AVERSA methylphenidate are now part of the pipeline, targeting existing products with abuse potential. The technology aims to deter misuse while ensuring drug availability. A feasibility agreement with Kindeva Drug Delivery has initiated the development of AVERSA Fentanyl, enhancing Nutriband's strategic focus on abuse deterrent formulations.
FAQ
What is the current stock price of Nutriband (NTRBW)?
